(Q34654024)

3 August 2017

1 reference

title

CD3-specific antibodies: a portal to the treatment of autoimmunity (English)

1 reference

3 August 2017

1 reference

Lucienne Chatenoud

0 references

Jeffrey A Bluestone

series ordinal

object named as

Jeffrey A Bluestone

1 reference

3 August 2017

publication date

20 July 2007

1 reference

Nature Reviews Immunology

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

622-632

1 reference

Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes

3 August 2017

cites work

1 reference

Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.

31 March 2020

1 reference

Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy

31 March 2020

1 reference

Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)

31 March 2020

1 reference

Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes

31 March 2020

1 reference

Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice

31 March 2020

1 reference

Peptide therapy for diabetes in NOD mice

31 March 2020

1 reference

Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity

31 March 2020

1 reference

Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4,

31 March 2020

1 reference

Antigen-driven peripheral immune tolerance: suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen.

31 March 2020

1 reference

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group

31 March 2020

1 reference

Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes

31 March 2020

1 reference

Effects of insulin in relatives of patients with type 1 diabetes mellitus

31 March 2020

1 reference

Antigen-specific therapies in multiple sclerosis.

31 March 2020

1 reference

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

31 March 2020

1 reference

Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading

31 March 2020

1 reference

Antigen‐driven tissue‐specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein‐induced experimental autoimmune encephalomyelitis in the SJL mouse

31 March 2020

1 reference

Determinant Spreading of T Helper Cell 2 (Th2) Responses to Pancreatic Islet Autoantigens

31 March 2020

1 reference

Immune therapies of autoimmune diseases: are we approaching a real cure?

31 March 2020

1 reference

The mechanisms, diagnosis, and management of severe asthma in adults

31 March 2020

1 reference

Strategies to improve long-term outcomes after renal transplantation

31 March 2020

1 reference

The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation

31 March 2020

1 reference

Alemtuzumab (Campath-1H): a systematic review in organ transplantation

31 March 2020

1 reference

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

31 March 2020

1 reference

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

31 March 2020

1 reference

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

31 March 2020

1 reference

Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody.

31 March 2020

1 reference

Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy

31 March 2020

1 reference

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

31 March 2020

1 reference

Maintenance of Human T Cell Anergy: Blocking of IL-2 Gene Transcription by Activated Rap1

31 March 2020

1 reference

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

31 March 2020

1 reference

31 March 2020

1 reference

Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor.

31 March 2020

1 reference

Cyclosporin A sensitivity of the NF-kappa B site of the IL2R alpha promoter in untransformed murine T cells

31 March 2020

1 reference

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients

31 March 2020

1 reference

Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]

31 March 2020

1 reference

Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4

31 March 2020

1 reference

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis

31 March 2020

1 reference

CD3-specific antibody-induced active tolerance: from bench to bedside

31 March 2020

1 reference

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

31 March 2020

1 reference

Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes

31 March 2020

1 reference

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

31 March 2020

1 reference

In vitro characterization of five humanized OKT3 effector function variant antibodies.

31 March 2020

1 reference

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

31 March 2020

1 reference

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

31 March 2020

1 reference

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

31 March 2020

1 reference

PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1

31 March 2020

1 reference

Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids

31 March 2020

1 reference

Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-γ, interleukin 3 and interleukin 6 release after triggering of the CD33/T cell receptor activation pathway

31 March 2020

1 reference

Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo

31 March 2020

1 reference

Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome

31 March 2020

1 reference

Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

31 March 2020

1 reference

Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin

31 March 2020

1 reference

Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

31 March 2020

1 reference

beta-cell failure in diabetes and preservation by clinical treatment

31 March 2020

1 reference

Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.

31 March 2020

1 reference

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

31 March 2020

1 reference

The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes

31 March 2020

1 reference

CTLA4Ig: bridging the basic immunology with clinical application

31 March 2020

1 reference

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

31 March 2020

1 reference

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

31 March 2020

1 reference

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

31 March 2020

1 reference

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

31 March 2020

1 reference

Co-stimulatory blockade as therapy for rheumatoid arthritis

31 March 2020

1 reference

Development of anti-TNF therapy for rheumatoid arthritis

31 March 2020

1 reference

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

31 March 2020

1 reference

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

31 March 2020

1 reference

Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.

31 March 2020

1 reference

Dendritic cells: emerging pharmacological targets of immunosuppressive drugs

31 March 2020

1 reference

mTOR--beyond transplantation

31 March 2020

1 reference

Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance

31 March 2020

1 reference

Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients

31 March 2020

1 reference

Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T

31 March 2020

1 reference

Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice

31 March 2020

1 reference

Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy

31 March 2020

1 reference

Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.

31 March 2020

1 reference

New reagents on the horizon for immune tolerance

31 March 2020

1 reference

Advances in biologic therapy for ulcerative colitis and Crohn's disease

31 March 2020

1 reference

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

31 March 2020

1 reference

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

31 March 2020

1 reference

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

31 March 2020

1 reference

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody

31 March 2020

1 reference

Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse

31 March 2020

1 reference

Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma

31 March 2020

1 reference

Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice

31 March 2020

1 reference

Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes

31 March 2020

1 reference

Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRI2134

1 reference

3 August 2017

1 reference